Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative ReviewVincent T. Martin, Robert Pallay, Eric Pearlman et al.|Advances in Therapy|2020Cited by 17
A phase IV clinical trial of gastrointestinal motility in adult patients with migraine before and after initiation of a calcitonin gene‐related peptide ligand (galcanezumab) or receptor (erenumab) antagonistDavid Kudrow, Eric Pearlman, Linda Anh B. Nguyen et al.|Headache The Journal of Head and Face Pain|2022Cited by 13
Galcanezumab Provides Consistent Efficacy Throughout the Dosing Interval Among Patients with Episodic and Chronic Migraine: A Post Hoc AnalysisPatricia Pozo‐Rosich, Eric Pearlman, Mallikarjuna Rettiganti et al.|Advances in Therapy|2021Cited by 12